1. Key Insights

2. Report Introduction

3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview at a Glance

3.1. Market Share (%) Distribution of CIDP by Therapies in the 7MM in 2020

3.2. Market Share (%) Distribution of CIDP by Therapies in the 7MM in 2034

4. Executive Summary

5. Key Events

6. Disease Background and Overview

6.1. Introduction

6.2. Signs and symptoms

6.3. Causes

6.4. Types

6.5. Pathogenesis of CIDP

6.6. Diagnosis

6.6.1. Differential Diagnosis

6.6.2. Diagnostic Algorithm

6.6.3. Misdiagnosis of CIDP

6.6.4. Diagnostic Guidelines

6.7. Treatment

6.7.1. Treatment Guidelines

6.7.2. Treatment Algorithm

7. Epidemiology and Market Methodology

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale: 7MM

8.2.1. Diagnosed Prevalent Cases of CIDP

8.2.2. Gender-specific Diagnosed Prevalent Cases of CIDP

8.2.3. Age-specific Diagnosed Prevalent Cases of CIDP

8.2.4. Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP

8.2.5. Refractory Cases of CIDP

8.3. Diagnosed Prevalent Cases of CIDP in the 7MM

8.4. The United States

8.4.1. Total Diagnosed Prevalent Cases of CIDP in the US

8.4.2. Gender-specific Diagnosed Prevalent Cases of CIDP in the US

8.4.3. Age-specific Diagnosed Prevalent Cases of CIDP in the US

8.4.4. Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP in the US

8.4.5. Refractory Cases of CIDP in the US

8.5. EU4 and the UK

8.5.1. Total Diagnosed Prevalent Cases of CIDP in EU4 and the UK

8.5.2. Gender-specific Diagnosed Prevalent Cases of CIDP in EU4 and the UK

8.5.3. Age-specific Diagnosed Prevalent Cases of CIDP in EU4 and the UK

8.5.4. Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP in EU4 and the UK

8.5.5. Refractory Cases of CIDP in EU4 and the UK

8.6. Japan

8.6.1. Total Diagnosed Prevalent Cases of CIDP in Japan

8.6.2. Gender-specific Diagnosed Prevalent Cases of CIDP in Japan

8.6.3. Age-specific Diagnosed Prevalent Cases of CIDP in Japan

8.6.4. Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP in Japan

8.6.5. Refractory cases of CIDP in Japan

9. Patient Journey

10. Marketed Therapies

10.1. Key Cross Competition

10.2. HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda

10.2.1. Product Description

10.2.2. Regulatory milestones

10.2.3. Other Developmental Activities

10.2.4. Clinical Development

10.2.5. Safety and Efficacy

10.3. VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx

10.3.1. Product Description

10.3.2. Regulatory Milestones

10.3.3. Other Developmental Activities

10.3.4. Clinical development

10.3.5. Safety and Efficacy

10.4. GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda

10.4.1. Product Description

10.4.2. Regulatory milestones

10.4.3. Clinical development

10.4.4. Safety and Efficacy

10.5. PANZYGA (Immune Globulin Intravenous [Human] – Ifas 10% Liquid Preparation): Pfizer/Octapharma

10.5.1. Product Description

10.5.2. Regulatory Milestones

10.5.3. Other Developmental Activities

10.5.4. Clinical Development

10.5.5. Safety and Efficacy

10.6. PRIVIGEN (Immune Globulin Intravenous [Human] – 10% Liquid Preparation): CSL Behring

10.6.1. Product Description

10.6.2. Regulatory milestones

10.6.3. Clinical development

10.6.4. Safety and Efficacy

10.7. HIZENTRA (Immune Globulin Gubcutaneous [Human] – 20% Liquid Preparation): CSL Behring

10.7.1. Product Description

10.7.2. Regulatory Milestones

10.7.3. Other Developmental Activities

10.7.4. Clinical Development

10.7.5. Safety and Efficacy

11. Emerging Drug Profiles

11.1. Key Cross Competition of Emerging Drugs

11.2. Riliprubart (SAR445088): Sanofi

11.2.1. Drug Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Trials Information

11.2.4. Safety and Efficacy

11.2.5. Analysts’ View

11.3. Nipocalimab: Janssen Research and Development, LLC

11.3.1. Drug Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Trials Information

11.3.4. Safety and Efficacy

11.3.5. Analysts’ View

11.4. Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences, Inc.

11.4.1. Drug Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Trials Information

11.4.4. Analysts’ View

12. CIDP: Market Analysis

12.1. Key Findings

12.2. Key Market Forecast Assumptions

12.2.1. Cost Assumptions and Rebates

12.2.2. Pricing Trends

12.2.3. Analogue Assessment

12.2.4. Launch Year and Therapy Uptake

12.3. Market Outlook

12.4. Attribute Analysis

12.5. Total Market Size of CIDP in the 7MM

12.6. Market Size of CIDP by Therapies in the 7MM

12.7. Market Size of CIDP in the United States

12.7.1. Total Market Size of CIDP

12.7.2. Market Size of CIDP by Therapies in the United States

12.8. Market Size of CIDP in EU4 and the UK

12.8.1. Total Market Size of CIDP

12.8.2. Market Size of CIDP by Therapies in EU4 and the UK

12.9. Market Size of CIDP in Japan

12.9.1. Total Market Size of CIDP

12.9.2. Market Size of CIDP by Therapies in Japan

13. Key Opinion Leaders’ Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

16.1. The United States

16.1.1. Center for Medicare and Medicaid Services (CMS)

16.2. In EU4 and the UK

16.2.1. Germany

16.2.2. France

16.2.3. Italy

16.2.4. Spain

16.2.5. The United Kingdom

16.3. Japan

16.3.1. MHLW

17. Appendix

17.1. Acronyms and Abbreviations

17.2. Bibliography

17.3. Report Methodology

18. DRA Reports Capabilities

19. Disclaimer

20. About DRA Reports